Please select the option that best describes you:
Topics:
Radiation Oncology • Pediatric Hematology/Oncology • Medical Oncology • Survivorship • Chemotherapy • Drug Toxicity • Cardio-Oncology
What, if any, cardioprotective measures beyond dexrazoxane may be used to minimize cardiac risk during or after chemo- or radio-therapy?
Are there other measures, pharmocologic or adjunctive, that can be used or are under investigation to mitigate cardiotoxicity related to chemo- or radio-therapy?
Answer from: at Community Practice
For cardioprotection, I would recommend:
Baseline cardiovascular risk stratification, can use the HFA-ICOS risk calculator (https://www.cancercalc.com/hfa-icos_cardio_oncology_risk_assessment.php), consider alternative chemotherapies if very high risk and alternative therapy equal efficacy.
...
Sign in or Register to read more
Answer from: at Community Practice
Although pediatric patients rarely have cardiac co-morbidities at the time of diagnosis, we also monitor and treat high blood pressures carefully and follow echos throughout treatment. There is no data in pediatrics to utilize statin drugs during therapy, although we follow lipids in our survivor an...